Sentence examples for many preclinical models from inspiring English sources

Inhibition of mTOR signalling by rapamycin activates autophagy that in turn causes growth arrest in many preclinical models of cancer (Ravikumar et al, 2004).

Efficient gene transfer to cardiomyocytes using adeno-associated virus (AAV) vectors has been shown in many preclinical models (reviewed in ref)., and promising results have been reported in the phase 2 CUPID clinical trial overexpressing sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) via AAV-1 in patients with advanced heart failure.

Furthermore, inhibitors of histone deacetylases have proven to be successful in many preclinical cancer models and have shown encouraging results in clinical trials (Minucci and Pelicci, 2006).

This localized resistance to VDAs has been reported in many preclinical tumor models and in clinical trials in different types of malignancies 4. Localized resistance is likely due to significant heterogeneity within a solid tumor.

Although many preclinical animal models showed ectopic as well as orthotopic bone formation following implantation of 3D cell-loaded constructs, questions regarding the optimal osteogenic differentiation method for hMSCs as well as an effective initiation of osteogenesis in vivo have not been finally clarified.

There was no significant relationship between basal T1 value and ΔTVol in keeping with previous observations in many different preclinical models [ 7] that basal T1 cannot predict response.

In preclinical models, many of the direct anticancer effects of metformin have been attributed to activation of AMPK via increased T172 phosphorylation by LKB1 [ 22].

As it is quite complex to study responses of metastases in a preclinical model, there have not been many preclinical studies on therapies in metastatic models.

It has been reported that Cdk inhibitors could inhibit tumour cell growth in preclinical models, but many questions remain about which Cdks should be targeted for anticancer therapy.

However, many of these trials require preclinical models for evidence of efficacy, and most of these models currently fail to account for multiple somatic events that contribute to therapeutic response.

For this reason, apoptosis of NB cells has become the goal of many studies using novel therapeutics in preclinical models.